scholarly journals Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry

2016 ◽  
Vol 23 (6) ◽  
pp. 556 ◽  
Author(s):  
C.S. Bhugwandass ◽  
J.M.A. Pijnenborg ◽  
B. Pijlman ◽  
N.P.M. Ezendam
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Population Based ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Early Stage Ovarian Cancer

Background There is wide variation in the application of adjuvant chemotherapy in early-stage epithelial ovarian cancer. Our aim was to assess differences in health-related quality of life (hrqol) between patients with early-stage ovarian cancer who did or did not receive chemotherapy as adjuvant treatment.Methods All patients diagnosed with early-stage ovarian cancer between 2000 and 2010 within the population-based Eindhoven Cancer Registry (n = 191) were enrolled in this study. Patients were requested to complete questionnaires, including the cancer-specific (qlq-C30) and ovarian cancer-specific (qlq-OV28) quality of life measures from the European Organisation for Research and Treatment of Cancer. Primary outcome measures were the generic- and cancer-specific domain scores for hrqol in ovarian cancer survivors.Results Of the 107 patients (56%) who returned the questionnaires, 57 (53.3%) had received adjuvant chemotherapy and 50 (46.7%) had been treated with surgery alone. Significant differences in hrqol between those groups were found in the symptom scales for peripheral neuropathy, attitude toward sickness, and financial situation, with worse scores in the chemotherapy group.Conclusions Results of our study show that patients who receive adjuvant chemotherapy have a significantly worse score for 3 aspects of hrqol. Efforts should be made to reduce use of adjuvant chemotherapy in early-stage ovarian cancer. Moreover, preventive strategies to improve long-term quality of life for those who need adjuvant chemotherapy should be explored.

The predictive validity of health-related quality of life measures: mortality in a longitudinal population-based study

2007 ◽  
Vol 16 (9) ◽  
pp. 1539-1546 ◽  
Author(s):  
Mark S. Kaplan ◽  
Jean-Marie Berthelot ◽  
David Feeny ◽  
Bentson H. McFarland ◽  
Saeeda Khan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Predictive Validity ◽  
Population Based ◽  
Health Related Quality ◽  
Population Based Study ◽  
Quality Of Life Measures ◽  
Related Quality ◽  
Health Related

scholarly journals Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens

2021 ◽  
Author(s):  
Daphne H. M. Jacobs ◽  
Ramona K. Charaghvandi ◽  
Nanda Horeweg ◽  
John H. Maduro ◽  
Gabrielle Speijer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Irradiation ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Over Time

Abstract Purpose To evaluate and compare health-related quality of life (HRQL) of women with early-stage breast cancer (BC) treated with different radiotherapy (RT) regimens. Methods Data were collected from five prospective cohorts of BC patients treated with breast-conserving surgery and different RT regimens: intraoperative RT (IORT, 1 × 23.3 Gy; n = 267), external beam accelerated partial breast irradiation (EB-APBI, 10 × 3.85 Gy; n = 206), hypofractionated whole breast irradiation(hypo-WBI, 16 × 2.67 Gy; n = 375), hypo-WBI + boost(hypo-WBI-B, 21–26 × 2.67 Gy; n = 189), and simultaneous WBI + boost(WBI-B, 28 × 2.3 Gy; n = 475). Women ≥ 60 years with invasive/in situ carcinoma ≤ 30 mm, cN0 and pN0-1a were included. Validated EORTC QLQ-C30/BR23 questionnaires were used to asses HRQL. Multivariable linear regression models adjusted for confounding (age, comorbidity, pT, locoregional treatment, systemic therapy) were used to compare the impact of the RT regimens on HRQL at 12 and 24 months. Differences in HRQL over time (3–24 months) were evaluated using linear mixed models. Results There were no significant differences in HRQL at 12 months between groups except for breast symptoms which were better after IORT and EB-APBI compared to hypo-WBI at 12 months (p < 0.001). Over time, breast symptoms, fatigue, global health status and role functioning were significantly better after IORT and EB-APBI than hypo-WBI. At 24 months, HRQL was comparable in all groups. Conclusion In women with early-stage breast cancer, the radiotherapy regimen did not substantially influence long-term HRQL with the exception of breast symptoms. Breast symptoms are more common after WBI than after IORT or EB-APBI and improve slowly until no significant difference remains at 2 years posttreatment.

Sign in / Sign up

Export Citation Format

Share Document